id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-335767-omm04fg5	Raabe, Vanessa N	Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials	2020-05-27		.txt	text/plain	1468	57	32	Not only do children and the medical community lose out on opportunities to gain the highest level of clinical evidence for efficacy in a vulnerable population, but due to the lack of availability of pediatric trials, many children hospitalized for COVID-19 are receiving off-label use of therapeutic agents with unproven benefit against COVID-19. In addition to offering enhanced safety monitoring, enrollment of children in clinical trials ensures that parents and older children are fully informed of the potential risks and benefits associated with use of the therapeutic agent, a conversation often omitted when medications are prescribed off-label. Inclusion of children in these clinical trials is feasible under current regulations, provides direct benefit to pediatric trial participants from a safety perspective compared to off-label prescribing, and provides systematic collection of the highest quality of evidence for COVID-19 therapeutics in a vulnerable population where SARS-CoV-2 infection behaves differently from adults.	./cache/cord-335767-omm04fg5.txt	./txt/cord-335767-omm04fg5.txt